BIOLASE, Inc. (NASDAQ:BIOL) Q2 2019 Earnings Conference Call Transcript
Aug 08, 2019 • 04:30 pm ET
Good day, everyone, and welcome to the BIOLASE 2019 Second Quarter Financial Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Todd Kehrli of the EVC Group. Please go ahead, sir.
Thank you, operator. Good afternoon, everyone, and thank you for joining us today to discuss BIOLASE's financial results for the 2019 second quarter ended June 30, 2019. On the call today from BIOLASE are Todd Norbe, President and Chief Executive Officer; and John Beaver, Executive Vice President and Chief Financial Officer.
Management will review the Company's operating performance for the second quarter before opening the call for questions. Before we begin, I'd like to remind everyone that a number of forward-looking statements, which are any statements that are not historical facts, will be made during this presentation, including forward-looking statements regarding the Company's strategic initiatives and financial performance. These forward-looking statements are based on BIOLASE's current expectations and are subject to a variety of risks and uncertainties that could cause the Company's actual results to differ materially from the statements contained in this presentation.
Such forward-looking statements only represent the Company's view as of today, August 8, 2019. These risks are discussed in the Company's filings with the Securities and Exchange Commission. A replay of this conference call will be available on BIOLASE website shortly after the completion of today's call. When listening to this call, please refer to the news release issued earlier today announcing the Company's 2019 second quarter results. If you do not have a copy of the news release, it is available on the Investors section on the BIOLASE website at biolase.com.
BIOLASE's financial results can also be found on the Company's quarterly report on Form 10-Q, which will be filed with the SEC. The tables we provided in today's news release offer additional financial information, so we encourage you to review them. The tables include a reconciliation of unaudited GAAP net loss and net loss per share to non-GAAP net loss and net loss per share as well as the details of the Company's other non-GAAP disclosures.
With that, I'm pleased to turn the call over to BIOLASE's President and Chief Executive Officer, Todd Norbe.
Todd A. Norbe
Thanks, Todd, and thanks, everyone, for joining us this afternoon. I appreciate your interest and continued support of BIOLASE.
Today is my one-year anniversary as CEO of BIOLASE. We've accomplished a lot over the last year and still have much to do. Continuing -- coming from the dental industry, I was attracted to this technology and the opportunity that existed at BIOLASE to create a new standard of dental care. Our all-tissue Waterlase technology continues to amaze clinicians and patients alike with its capabilities, as we are well on our way to building a commercial infrastructure to support this great technology, allowing for expanded reach. During this past year, we have put in place the business processes that are necessary to successfully align BIOLASE's innovative technology with an approach